Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
about
Cardiovascular disease and type 1 diabetes: prevalence, prediction and management in an ageing populationSoluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary SyndromeLow levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or realityRAGE: a new frontier in chronic airways diseaseHigher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study.Evaluation of circulating sRAGE in osteoporosis according to BMI, adipokines and fracture risk: a pilot observational study.Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical updateSoluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities studyTotal soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trialSerum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan StudyDiabetes and the risk of heart failureGenetics of Plasma Soluble Receptor for Advanced Glycation End-Products and Cardiovascular Outcomes in a Community-based Population: Results from the Atherosclerosis Risk in Communities StudyRelationship of Soluble RAGE with Insulin Resistance and Beta Cell Function during Development of Type 2 Diabetes Mellitus.Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight lossCalibrated integrated backscatter and myocardial fibrosis in patients undergoing cardiac surgerySoluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up studyAstragalus membranaceus inhibits inflammation via phospho-P38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-κB pathways in advanced glycation end product-stimulated macrophages.Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.Prognostic value of endothelial dysfunction in type 1 diabetes mellitus.Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes.Role of Glycated Proteins in the Diagnosis and Management of Diabetes: Research Gaps and Future Directions.Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory.Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort.Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study.Comment on: Selvin et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013;62:2116-2121.Advances in cardiovascular research. 15th Annual Meeting of the European Council for Cardiovascular Research (ECCR). La Colle sur Loup, France, 8–10 October 2010.Effects of bergenin on methylglyoxal-induced damage in osteoblastic MC3T3-E1 cells.Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats.Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes.Ratio of serum levels of AGEs to soluble RAGE is correlated with trimethylamine-N-oxide in non-diabetic subjects.The Relationship of Serum Soluble Receptor for Advanced Glycation End Products (sRAGE) and Carboxymethyl Lysine (CML) to the Incidence of Diabetic Nephropathy in Persons With Type 1 Diabetes.Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease.
P2860
Q26777077-FA06F85E-B057-4112-857C-41E018A039D2Q26780488-289EE7D1-101C-4D4C-8144-EF89CCA1C2C1Q26859793-01797C83-FFE3-41AC-8AB3-EDC1D6923DFAQ27025295-742542EE-A148-42F4-8977-03719F16DCF3Q33592848-B2D545D6-D70C-44CE-BB2B-B9A0716BFDD2Q33801160-6599CA1C-4B27-4EFE-B26D-D0E96989F25BQ34286094-1464456C-8A3D-47F1-BC8D-AAE9099C605AQ34564061-D6375DE8-86B4-4B6D-A3CC-307859E2F45EQ35152739-BC49BCBC-F937-4859-8A7B-93173D735BB7Q35180065-A0716999-3A5F-4973-94AD-CFDB249F7F1EQ35234754-3AA01529-E935-499A-9406-B9AEF7385236Q35571144-D9939352-B8B0-4152-B2CE-E332DB25A67EQ35666321-A73B40B6-39BD-4651-A7AA-5B9FF5240FA1Q35674689-C5AA8DE2-63B1-447D-850C-F1813E70430DQ35876768-1845D932-D48F-475D-AA27-08C4156D822EQ36012175-98AFBB5B-52EB-4F2F-A96C-22CD4C854802Q36091982-9A5AE84B-B2AC-491C-A89C-5659D6B93FF5Q36197219-E69A57FD-6487-4E5E-9D24-A0F64ADED67AQ37693552-29D48B7B-081A-44B0-8BA3-8540E192952BQ38200957-781708BF-051F-4834-9FB3-2A32D5C68B04Q38260398-295EF8F3-2DFC-4A85-AB3E-8D1220377D44Q38651423-439D67B3-588E-4C25-8F28-18F19D895151Q38837915-A51688DC-069B-4810-8B8A-17BD39BD4D7AQ38936100-F3138A02-8B81-41A2-9869-CC6BC6893C17Q39190228-535C7D63-412C-4593-A12F-F12151700300Q39313922-32003136-A339-4174-A71C-6E3A29254D9CQ40298930-5B182D6B-FA00-4A2E-8254-2702A4A7FF3AQ42290483-0BF3ACCE-6543-4905-B108-B11B48EA1B6FQ42970461-60595CFD-E514-4EA2-9721-189CC31BD324Q44514640-44DB5687-B47D-47F4-B068-2AACB79325CFQ46259674-AC4BB3B8-2767-4742-A854-0A8150654BA0Q47579007-FAF7F304-8BC1-438F-ABC7-4AE52AD82165Q47994395-0C8C7A35-2F2B-4111-8174-5E2CCDFBD41DQ48243790-7B1C1338-5B98-4065-A826-C2060CB664CFQ48255979-95A5E607-2C58-46C7-8E1C-30E2C549F65CQ51371652-FB61C7F4-4467-4005-8809-FE3978793A90Q54605224-B8F3E59B-85F8-48FB-BEB5-96A84C8E03C0
P2860
Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Higher plasma soluble Receptor ...... es: a 12-year follow-up study.
@ast
Higher plasma soluble Receptor ...... es: a 12-year follow-up study.
@en
Higher plasma soluble Receptor for Advanced Glycation End Products
@nl
type
label
Higher plasma soluble Receptor ...... es: a 12-year follow-up study.
@ast
Higher plasma soluble Receptor ...... es: a 12-year follow-up study.
@en
Higher plasma soluble Receptor for Advanced Glycation End Products
@nl
prefLabel
Higher plasma soluble Receptor ...... es: a 12-year follow-up study.
@ast
Higher plasma soluble Receptor ...... es: a 12-year follow-up study.
@en
Higher plasma soluble Receptor for Advanced Glycation End Products
@nl
P2093
P2860
P50
P356
P1433
P1476
Higher plasma soluble Receptor ...... es: a 12-year follow-up study.
@en
P2093
Hans-Henrik Parving
Johanna W M Nin
Lise Tarnow
Martin H Prins
P2860
P304
P356
10.2337/DB09-1509
P407
P50
P577
2010-06-03T00:00:00Z